Showing posts with label adult stem cells. Show all posts
Showing posts with label adult stem cells. Show all posts

Tuesday, August 17, 2010

Mayo’s “Smart” Adult Stem Cells Repair Hearts

(BUSINESS WIRE)--Mayo Clinic investigators, with Belgian collaborators, have demonstrated that rationally “guided” human adult stem cells can effectively heal, repair and regenerate damaged heart tissue. The findings — called “landmark work” in an accompanying editorial — appear in today’s Journal of the American College of Cardiology.

Stem cells isolated from patients have normally a limited capacity to repair the heart. This innovative technology boosts the regenerative benefit by programming adult stem cells to acquire a cardiac-like profile. Primed by a cocktail of recombinant cardiogenic growth factors, mesenchymal stem cells (MSCs) harvested from the bone marrow of a cohort of patients with coronary artery disease showed “superior functional and structural benefit without adverse side effects” over a 1-year follow-up in a model of heart failure according to the study.

Significance of the Findings

“These findings provide proof-of-principle that “smart” adult stem cells have added benefit in repairing the heart, providing the foundation for further clinical evaluation,” says Andre Terzic, M.D., Ph.D., Mayo Clinic researcher and senior investigator of the study. “The successful use of guided “lineage specified” human stem cells is based on natural cardiogenic cues” adds Atta Behfar, M.D., Ph.D. first author of the study. The pre-clinical data reported in this seminal paper have cleared the way for safety and feasibility trials in humans, which were recently conducted in Europe.

In their editorial, Eduardo Marban, M.D., Ph.D., and Konstantinos Malliaras, M.D., of Cedars-Sinai Heart Institute, in Los Angeles describe the Mayo approach as a “boot camp” for stem cells and also write that the study “… provides the first convincing evidence that MSCs, at least in vitro, can in fact become functional cardiomyocytes (heart cells)...”

The long-term potential of the findings include development of an effective regenerative medicine therapy for patients with chronic heart failure.

How It Was Done

Researchers obtained bone marrow-derived stem cells from heart disease patients undergoing coronary bypass surgery. Testing of these stem cells revealed that cells from two of 11 individuals showed an unusual capacity for heart repair. These rare cells demonstrated upregulated genetic transcription factors that helped identify a molecular signature identifying highly regenerative stem cells. The cardiogenic cocktail was then used to induce this signature in non-reparative patient stem cells to program their capacity to repair the heart. Mouse models with heart failure, injected with these cells, demonstrated significant heart function recovery along with improved survival rate after a year, compared to those treated with unguided stem cells or saline.

Specifically, researchers found that the heart tissue healed more effectively; that human cardiac and vascular cells were found participating in the regeneration, repair and strengthening of heart structures within the area of injury; and that scars and vestiges of heart damage appeared to fade away.

Authors include Atta Behfar, M.D., Ph.D.; Satsuki Yamada, M.D., Ph.D.; Ruben Crespo-Diaz; Jonathan Nesbitt; Lois Rowe; Carmen Perez-Terzic, M.D., Ph.D.; Andre Terzic, M.D., Ph.D. of Mayo Clinic; Vinciane Gaussin, Ph.D. and Christian Homsy, M.D., Cardio3 Biosciences, Mont-Saint-Guibert, Belgium; and Jozef Bartunek, M.D., Cardiovascular Center, Aalst, Belgium.

The research was supported by the National Institutes of Health, the American Heart Association, the Marriott Heart Disease Research Program, Cardio 3 Biosciences, the Ted Nash Long Life Foundation, the Ralph Wilson Medical Research Foundation, the Mayo Clinic General Mills Clinician-Investigator Fellowship, and Mayo Clinic.

Mayo Clinic and Drs. Andre Terzic and Atta Behfar have a financial interest associated with technology related to this research program. In accordance with the Bayh-Dole Act, Mayo Clinic has licensed that technology to Cardio 3 Biosciences in exchange for equity. No royalties have accrued to date to the institution or the inventors.

-----
Community News You Can Use
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page
Follow us on Twitter:  @GAFrontPage

Tuesday, June 23, 2009

The Alliance for the Advancement of Adult Stem Cell Therapy and Research Announces Successful Treatment of End-Stage Heart Disease with Stem Cells

(BUSINESS WIRE)--Zannos Grekos, MD, Associate Clinical Professor at Nova Southeastern University, has announced six month follow-up results for a patient treated with adult stem cells in a clinical study of idiopathic dilated cardiomyopathy. The clinical study is a collaborative effort among physicians at Regenocyte Therapeutic, an American stem cell therapy clinic; researchers and scientists from Theravitae, a biotechnology company from Israel; and physicians from the American Institute for Regenerative Medicine, Dominican Republic.

Leonard Narracci, 71 from Venice, Florida, underwent the adult stem cell therapy in October 2008. Since being diagnosed with idiopathic dilated cardiomyopathy and congestive heart failure, Narracci's ejection fraction was severely reduced at 18% (with normal being over 55%). Within three months of the treatment, his ejection fraction improved to 40% and it is now at 51%.

“It goes against traditional theory that we should try to fix damaged heart muscle, but we are generating new heart tissue with impressive results that improve cardiac function and quality of life,” said Dr. Leonel Fernandez Liriano, Professor of Medicine at Pontifical Catholic University School of Medicine (PCUSM), and the head of the cardiology team that treated the patient with adult stem cells.

Grekos states, “After comparing this patient’s echocardiogram and MUGA nuclear scans before and after treatment, we are very pleased to see a profound increase in cardiac function.”

Regenocyte Therapeutic has treated several similar patients and they are demonstrating correlative improvements. Grekos continues, “We have had success in the ischemic heart disease patients since 2006, and it is encouraging to see that the technology can now be applied to other diseases.” Regenocyte Therapeutic is also treating patients with pulmonary hypertension, COPD, kidney disease, peripheral artery disease, and early senile dementia.

Athina Kyritsis, MD, chair of Regenocyte’s Scientific Advisory Board, says the patient results are based upon several years of Regenocyte’s clinical experience in the treatment of numerous degenerative diseases with adult stem cell therapy. “We have had consistent success in generating viable heart tissue and growing new vessels, treating diseases like cardiomyopathy and peripheral vascular disease. With the increased circulation, healing of wounds and improvement in ejection fractions, it seemed a natural progression to approach cardiomyopathy in the same manner. I believe we have only begun to discover what adult stem cells can accomplish in altering the course of diseases until now thought to be untreatable.”

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page

Friday, January 23, 2009

FDA Stem Cell Approval Breakthrough Laudable

/PRNewswire/ -- Today the FDA announced approval for the first clinical trials on humans using Embryonic Stem Cells but Adult Stem Cell scientist Christian Drapeau says the experts may not be telling the whole story; Adult Stem Cells have greater potential with less risk.

"While the FDA approval is an exciting step forward toward freeing science from the shackles of politics," said Drapeau. "The expert commentary we're seeing surrounding the FDA's action is misleading."

Christian Drapeau, an early advocate of ASC science, posits that ACS are showing the greatest potential for scientific and medical advances.

Drapeau says that ASC can be a safer alternative to Embryonic Stem Cells because of a lower risk of tumor formation while studies show ASC to have comparable potential or even more in repairing damaged tissues or organs. This contradicts experts on morning talk shows who cast doubt on the efficacy of ACS research.

"The use of ASC requires a different thinking, but they can be as effective as ESC, if not more. ASC do not grow easily in vitro and they are not easy to re-program. But there are ways of using ASC that can be just as effective as methods using ESC, without the risk of tumor formation."

"Adult Stem Cells are showing great promise," notes Drapeau. "This is a very very important area of research right now and people must realize that Embryonic Stem Cells are not the only Stem Cell phenomenon out there."

"The scientific community is rejoicing today as a new age of medicine is ushered in concurrent with the Obama administration but the possibilities of Adult Stem Cell science are so mind boggling in terms of healing physical damage and the elimination of disease that the scientific community must focus on what works best, with the least amount of risk and the greatest scope of application," said Drapeau.

-----
www.fayettefrontpage.com
Fayette Front Page
www.georgiafrontpage.com
Georgia Front Page